Presentation Information
[P079]Evaluation of Intradermal Injection System (Immucise) for the Live Attenuated Vaccine, centrin-deficient Leishmania major (LmCen-/-), against Leishmaniasis
○Farzaneh Valanezhad1,2,3, Jalal Alshaweesh4, Shara Bakytbek1,2,3, Sakiko Shimizu5, Ryo Tanaka5, Yoichiro Iwase5, Risa Nakamura1,2,3, Greg Matlashewski6, Sreenivas Gannavaram7, Hira Nakhasi7, Abhay Satoskar8, Shinjiro Hamano1,2,3 (1. Department of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki (Japan), 2. Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, (Japan), 3. The Vaccine Research and Development Center, DEJIMA Infectious Disease Research Alliance (DIDA), Nagasaki University, Nagasaki (Japan), 4. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo (Japan), 5. TERUMO Corporation, Medical Care Solutions Company, Pharmaceutical Solutions Division, R&D (Japan), 6. Department of Microbiology and Immunology, McGill University, Montreal, QC, (Canada), 7. Division of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, 20993 US (United States of America), 8. Department of Pathology, The Ohio State University, Columbus, Ohio, (United States of America))
Password required to view
Comment
To browse or post comments, you must log in.Log in